18-hydroxy-19-norcorticosterone (18-OH-19-norcorticosterone) is a **synthetic steroid** that is structurally similar to the natural hormone **corticosterone**.
Here's why it's important in research:
* **Selective Mineralocorticoid Receptor (MR) Agonist:** 18-OH-19-norcorticosterone is a potent and selective agonist of the MR, meaning it binds to and activates the MR. This makes it a valuable tool for studying the role of the MR in various physiological processes.
* **Potential Therapeutic Applications:** Due to its selectivity for MR, 18-OH-19-norcorticosterone has potential therapeutic applications in conditions like:
* **Heart failure:** MR activation plays a role in heart failure progression. 18-OH-19-norcorticosterone might be useful in managing heart failure by targeting specific MR-mediated pathways.
* **Kidney disease:** MR activation can contribute to salt and water retention in kidney disease. Selective MR agonists like 18-OH-19-norcorticosterone could potentially be used to modulate these effects.
* **Neurological disorders:** MR signaling is involved in various brain functions. 18-OH-19-norcorticosterone might be explored as a potential treatment for conditions like Alzheimer's disease and anxiety.
* **Understanding MR Pharmacology:** 18-OH-19-norcorticosterone is a valuable tool for studying the pharmacology of the MR. Its selectivity allows researchers to differentiate the effects of MR activation from those of other steroid receptors like the glucocorticoid receptor (GR).
**Research using 18-OH-19-norcorticosterone is ongoing to better understand its potential therapeutic benefits and to refine its use in research settings.**
It's important to note that 18-OH-19-norcorticosterone is still under investigation, and its clinical applications are not yet fully established. More research is needed to determine its safety and efficacy in humans.
18-hydroxy-19-norcorticosterone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 130685 |
MeSH ID | M0146210 |
Synonym |
---|
111594-84-4 |
18-hydroxy-19-norcorticosterone |
19-norpregn-4-ene-3,20-dione, 11,18,21-trihydroxy-, (11beta)- |
18-oh-19-nc |
(8s,9s,10r,11s,13r,14s,17s)-11-hydroxy-17-(2-hydroxyacetyl)-13-(hydroxymethyl)-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one |
DTXSID40912234 |
11,18,21-trihydroxy-19-norpregn-4-ene-3,20-dione |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (33.33) | 18.7374 |
1990's | 6 (66.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |